Skip to main content
. Author manuscript; available in PMC: 2021 May 25.
Published in final edited form as: Leuk Res. 2017 Oct 14;63:34–40. doi: 10.1016/j.leukres.2017.10.002

Table 1.

Demographics and clinical characteristics of MF patients with and without thrombocytopenia.

Normal (Plt > 100 × 109/L) Thrombocytopenia (Plt < 100 × 109/L) Total p-value

n = 329 n = 89 n = 418
Age (mean, SD) 61.0 (12.15) 57.4 (12.67) 60.2 (12.34) 0.01
Gender (male) 156 (47.4%) 42 (47.2%) 198 (47.4%) 0.97
MF subtype 0.01
 Primary MF 217 (66%) 73 (82%) 290 (69.4%)
 ET-MF 64 (19.5%) 7 (7.9%) 71 (17%)
 PV-MF 48 (14.6%) 9 (10.1%) 57 (13.6%)
DIPSS risk 0.07
 Low 38 (19.3%) 5 (13.9%) 43 (18.5%)
 Intermediate-1 113 (57.4%) 15 (41.7%) 128 (54.9%)
 Intermediate-2 41 (20.8%) 14 (38.9%) 55 (23.6%)
 High 5 (2.5%) 2 (5.6%) 7 (3%)
Anemia (Hgb < 11 g/dL) 147 (44.8%) 68 (76.4%) 215 (51.6%) < 0.001
Leukopenia (WBC < 3.5 × 109/L) 35 (10.6%) 26 (29.2%) 61 (14.6%) < 0.001
Lab abnormality 172 (52.3%) 89 (100%) 261 (62.4%) < 0.001
Prior thrombosis 42 (12.9%) 5 (5.6%) 47 (11.3%) 0.06
Prior hemorrhage 14 (4.3%) 7 (7.9%) 21 (5.1%) 0.17
Required RBC transfusion 62 (19.1%) 31 (34.8%) 93 (22.5%) 0.002
Mean MPN duration (years, SD) 8.8 (8.33) 11.9 (10.86) 9.3 (8.81) 0.049

DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; Hgb, hemoglobin; MF, myelofibrosis; Plt, platelets; PV, polycythemia vera; RBC, red blood cell; SD, standard deviation; WBC, white blood cell.